In recent years, the development of the biopharmaceutical industry has been in full swing. Policy support, capital influx and technological innovation have formed a synergy to promote the industry into a period of rapid growth. Ankang, deputy to the National People's Congress and chairman of Hualan Bio, an important domestic leader in the field of blood products, vaccines and monoclonal antibodies, proposed during the two sessions of the National People's Congress that it is recommended to optimize the construction of the centralized procurement system for biopharmaceuticals and support the high-quality development of biopharmaceutical companies.

Recently, An Kang, deputy to the National People's Congress and chairman of Hualan Bio, said in an interview with Cailianshe reporters: "General Secretary Xi Jinping attended the private enterprise symposium and delivered an important speech, emphasizing that the development prospects of the private economy in the new era and new journey are broad and promising, and it is time for private enterprises and private entrepreneurs to show their talents. General Secretary Xi Jinping once again gave us private entrepreneurs a 'reassurance pill.'"

At the private enterprise symposium held some time ago, private entrepreneurs were required to strengthen their confidence, insist on innovation-driven, use scientific and technological innovation to expand and strengthen their main business, use industry to serve the country and bravely shoulder the responsibilities of the times, accelerate the development of new quality productivity, and inject new momentum into the high-quality development of the private economy.

Hualan Bio has also been working hard to implement this direction. Starting from a blood products company in Xinxiang, Henan, Hualan Bio has become a leading enterprise in my country's blood products, vaccine industry, and monoclonal antibody fields. In recent years, the company has promoted the optimization of the layout of the entire industrial chain of preventive and therapeutic drugs, solidly promoted the deep integration of scientific and technological innovation and industrial innovation, accelerated the development of new quality productivity, and strived to transform scientific research results into actual products to meet market demand and build an internationally competitive biopharmaceutical company.

In the field of blood products, Hualan Bio is one of the domestic manufacturers with the highest comprehensive utilization rate and the most complete range of coagulation factor products in the same industry; in the field of vaccines, Hualan Vaccine is the largest influenza vaccine manufacturer in my country; in the field of innovative drugs, Hualan Bio has built a differentiated competitive advantage through the genetic engineering technology platform. On November 21, 2024, bevacizumab injection (trade name: Anbeiyou@) developed by Hualan Gene, a company in which Hualan Bio holds a stake, was approved for listing by the National Medical Products Administration, becoming the first recombinant antibody drug approved in Henan Province. The company has formed a Huadu R&D system with more than 20 monoclonal antibody varieties, of which 10 monoclonal antibody varieties have obtained clinical trial approvals, covering colorectal cancer, lung cancer, liver cancer, cervical cancer, rheumatoid arthritis, breast cancer and many other treatment areas. After the product is successfully launched, it will greatly improve the problem of difficult and expensive drug use in this field in China.

This year's government work report pointed out that the implementation of the health-first development strategy will promote the coordinated development and governance of medical care, medical insurance, and medicine. Improve the drug price formation mechanism, formulate an innovative drug catalog, and support the development of innovative drugs.

Ankang said, "The country attaches more importance to the development of innovative drugs. Our biopharmaceutical companies will also accelerate R&D investment and use technologies such as artificial intelligence to empower new drug research and development. We will adhere to the innovation-driven development strategy and strive to develop drugs for the treatment of major diseases such as tumors and autoimmune diseases that endanger human life or health, provide patients with safe, effective and accessible drugs, and protect the health of the people."

Ankang also hopes that "the country will optimize the system construction in biopharmaceutical centralized procurement and government procurement bidding, and will be able to support the high-quality development of biopharmaceutical companies with greater efforts to create internationally competitive biopharmaceutical companies."

"In the future, Hualan Bio will continue to deepen the integrated layout of 'prevention-treatment', promote more innovative achievements to benefit people's livelihood, and contribute Hualan's strength to the Healthy China strategy." Ankang said.